Evidence map›Paper›PMID 38242283›Full record

ArticleJournal of molecular biology2024

Human In vitro Modeling Identifies Adjuvant Combinations that Unlock Antigen Cross-presentation and Promote T-helper 1 Development in Newborns, Adults and Elders.

Sanya Thomas, Jensen Pak, Simon Doss-Gollin, Kevin Ryff, Elisabeth Beijnen, Gabriel K Pedersen, Dennis Christensen, Ofer Levy, Simon D van Haren

Open access · hybridAbstract read
In one paragraph

Article in Journal of molecular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Sanya ThomasPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
Jensen PakPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
Simon Doss-GollinPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
Kevin RyffPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
Elisabeth BeijnenPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
Gabriel K PedersenCenter for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark; Department of Immunology and Microbiology, University of Copenhagen, Denmark.
Dennis ChristensenCenter for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.
Ofer LevyPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA; Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA; Broad Institute of MIT & Harvard, Cambridge, MA, USA.
Simon D van HarenPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA. Electronic address: simon.vanharen@childrens.harvard.edu.
Boston Children's Hospital · USStatens Serum Institut · DKBroad Institute · US

Funding

Transcriptomics to define biomarkers of neonatal vaccine immunogenicityU19AI118608 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2017 to 2021
$24.7M
Proteomics and Metabolomics Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthmaU19AI168643 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI OFER LEVY · 2022 to 2026
$10.0M
Dissecting the mechanism of age-specific adjuvant synergy in vitro and in vivoU01AI124284 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2016 to 2020
$2.9M
NIAID NIH HHS U01 AI124284NIAID NIH HHS U19 AI118608NIAID NIH HHS U19 AI168643
6 · The paper itself

Abstract

Adjuvants are vaccine components that can boost the type, magnitude, breadth, and durability of an immune response. We have previously demonstrated that certain adjuvant combinations can act synergistically to enhance and shape immunogenicity including promotion of Th1 and cytotoxic T-cell development. These combinations also promoted protective immunity in vulnerable populations such as newborns. In this study, we employed combined antigen-specific human in vitro models to identify adjuvant combinations that could synergistically promote the expansion of vaccine-specific CD4

Indexed as

Adjuvants, ImmunologicCross-PrimingTh1 CellsVaccine DevelopmentViral VaccinesAdolescentCytokinesDendritic CellsHumansInfant, NewbornToll-Like Receptor 9Young AdultAdjuvants, ImmunologicCytokinesToll-Like Receptor 9Viral VaccinesAdjuvantAdultCD4CD8Dendritic cellNewbornOlder adultVaccine

Identifiers

PMID38242283
PMCPMC10922990
OpenAlexW4391056169

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.